|View printer-friendly version|
|January 01, 2006 1:23 p.m.|
|Teva Announces Tentative Approval of Divalproex Sodium Delayed-Release Tablets|
Jerusalem, Israel, January 1, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Divalproex Sodium Delayed-Release Tablets USP, 125 mg, 250 mg and 500 mg. Final approval of this product is anticipated upon expiration of patent protection for the brand product in January 2008.